ResultsIQ

ResultsIQ › Latest results › Gland Pharma Limited

Gland Pharma Limited Q3 FY26 results deck summary

NSE: GLAND · BSE: 543245

Results deck of 28 Jan 2026, summarised by AI from the filing.

Gland Pharma Q3 FY26 revenue ₹16,954 mn, up 22% YoY, with Adj. PAT ₹2,797 mn, up 37% YoY.

Key takeaways

  1. Revenue Q3 FY26 revenue ₹16,954 mn, up 22% YoY from ₹13,841 mn and 14% QoQ from ₹14,869 mn.
  2. Adj. PAT Q3 FY26 Adj. PAT ₹2,797 mn, up 37% YoY from ₹2,047 mn and 52% QoQ from ₹1,837 mn.
  3. Cenexi EBITDA Cenexi EBITDA turned positive at €1.4 mn in Q3 FY26 from -€4 mn in Q3 FY25 and -€6 mn in Q2 FY26.
  4. US launches Nine molecules launched in the USA this quarter, including Argatroban, Acetazolamide and Doxycycline.
  5. Other Core Markets Lower uptake in a few products led to a decline in base business in Other Core Markets in Q3 FY26.

Original filing on BSE

Gland Pharma Limited Q1 FY27 results

As filed: Revenue ₹1,800 cr (+20% year on year), EBITDA ₹489 cr (+33% year on year), PAT ₹317 cr (+47% year on year), EBITDA margin 27.2% (+275 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹1,743 cr (+22% year on year), EBITDA ₹513 cr (+48% year on year), PAT ₹367 cr (+96% year on year), EBITDA margin 29.4% (+509 bps). Score 67 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit growth was well above it. EBITDA margin rose 509 bps year on year. Share price after the results: +21.1% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹1,695 cr (+23% year on year), EBITDA ₹435 cr (+21% year on year), PAT ₹261 cr (+28% year on year), EBITDA margin 25.7% (−36 bps). Score 51 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin fell 36 bps year on year. Share price after the results: +7.8% in 30 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹1,487 cr (+6% year on year), EBITDA ₹314 cr (+6% year on year), PAT ₹184 cr (+12% year on year), EBITDA margin 21.1% (−1 bps). Score 32 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin was flat year on year. Other income 30% of PBT. Tax rate 35%. Profit fell 14% from last quarter. Share price after the results: −10.2% in 30 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹1,506 cr (+7% year on year), EBITDA ₹368 cr (+39% year on year), PAT ₹215 cr (+49% year on year), EBITDA margin 24.4% (+553 bps). Score 57 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA and profit growth were above it. EBITDA margin rose 553 bps year on year. Share price after the results: −4.0% in 30 days (Nifty 500: +0.1%).
  • Q4 FY25: Revenue ₹1,425 cr (−7% year on year), EBITDA ₹347 cr (−3% year on year), PAT ₹187 cr (−3% year on year), EBITDA margin 24.4% (+99 bps). Score 36 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was in line with it. EBITDA margin rose 99 bps year on year. Tax rate 35%. Profit fell 9% from last quarter. Share price after the results: +13.9% in 30 days (Nifty 500: +0.8%).
  • Q3 FY25: Revenue ₹1,384 cr (−10% year on year), EBITDA ₹360 cr (+1% year on year), PAT ₹205 cr (+7% year on year), EBITDA margin 26.0% (+297 bps). Score 41 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was below it; profit growth was in line with it. EBITDA margin rose 297 bps year on year.
  • Q2 FY25: Revenue ₹1,406 cr (+2% year on year), EBITDA ₹297 cr (−8% year on year), PAT ₹164 cr (−15% year on year), EBITDA margin 21.1% (−247 bps). Score 19 of 100, Below trend. EBITDA margin fell 247 bps year on year. Tax rate 36%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Gland Pharma Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.